Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
AJNR Am J Neuroradiol ; 35(6 Suppl): S44-54, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24831591

ABSTRACT

Molecular imaging is the visualization, characterization, and measurement of biologic processes at the molecular and cellular levels in humans and other living systems. Molecular imaging techniques such as MR spectroscopy and PET have been used to explore the molecular pathophysiology of depression and assess treatment responses. MR spectroscopy is a noninvasive technique that assesses the levels of biochemical metabolites in the brain, while PET uses radioligands injected in the bloodstream that have high binding affinity for target molecules. MR spectroscopy findings suggest a role for glutamate/glutamine and gamma-aminobutyric acid in depression. PET has generally failed to find a correlation between radioligand binding potential and depression severity or treatment response, though it may offer promise in distinguishing responders and nonresponders to treatment. A major challenge for both modalities is that depression is a heterogeneous, multifactorial disorder, while MR spectroscopy and PET are limited to examining a few metabolites or a single radioligand at a time. This difference makes a comprehensive evaluation of neurochemical changes in the brain difficult.


Subject(s)
Brain/metabolism , Depressive Disorder/diagnostic imaging , Depressive Disorder/metabolism , Magnetic Resonance Spectroscopy/methods , Molecular Imaging/methods , Positron-Emission Tomography/methods , Humans
2.
Genes Brain Behav ; 11(3): 352-9, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22225729

ABSTRACT

The brain-derived neurotrophic factor (BDNF) Val(66) Met allelic variation is linked to both the occurrence of mood disorders and antidepressant response. These findings are not universally observed, and the mechanism by which this variation results in increased risk for mood disorders is unclear. One possible explanation is an epistatic relationship with other neurotransmitter genes associated with depression risk, such as the serotonin-transporter-linked promotor region (5-HTTLPR). Further, it is unclear how the coexistence of the BDNF Met and 5-HTTLPR S variants affects the function of the affective and cognitive control systems. To address this question, we conducted a functional magnetic resonance imaging (fMRI) study in 38 older adults (20 healthy and 18 remitted from major depressive disorder). Subjects performed an emotional oddball task during the fMRI scan and provided blood samples for genotyping. Our analyses examined the relationship between genotypes and brain activation to sad distractors and attentional targets. We found that 5-HTTLPR S allele carriers exhibited stronger activation in the amygdala in response to sad distractors, whereas BDNF Met carriers exhibited increased activation to sad stimuli but decreased activation to attentional targets in the dorsolateral prefrontal and dorsomedial prefrontal cortices. In addition, subjects with both the S allele and Met allele genes exhibited increased activation to sad stimuli in the subgenual cingulate and posterior cingulate. Our results indicate that the Met allele alone or in combination with 5-HTTLPR S allele may increase reactivity to sad stimuli, which might represent a neural mechanism underlying increased depression vulnerability.


Subject(s)
Brain-Derived Neurotrophic Factor/genetics , Depressive Disorder/genetics , Depressive Disorder/metabolism , Executive Function/physiology , Genetic Variation , Neurons/metabolism , Serotonin Plasma Membrane Transport Proteins/genetics , Aged , Alleles , Brain-Derived Neurotrophic Factor/deficiency , Depressive Disorder/psychology , Female , Genotype , Humans , Male , Methionine/genetics , Middle Aged , Neurons/pathology , Polymorphism, Genetic/genetics , Serotonin Plasma Membrane Transport Proteins/deficiency , Valine/genetics
3.
Mol Psychiatry ; 16(12): 1169-76, 2011 Dec.
Article in English | MEDLINE | ID: mdl-20856248

ABSTRACT

The brain serotonergic system has an essential role in the physiological functions of the central nervous system and dysregulation of serotonin (5-HT) homeostasis has been implicated in many neuropsychiatric disorders. The tryptophan hydroxylase-2 (TPH2) gene is the rate-limiting enzyme in brain 5-HT synthesis, and thus is an ideal candidate gene for understanding the role of dysregulation of brain serotonergic homeostasis. Here, we characterized a common, but functional single-nucleotide polymorphism (SNP rs1386493) in the TPH2 gene, which decreases efficiency of normal RNA splicing, resulting in a truncated TPH2 protein (TPH2-TR) by alternative splicing. TPH2-TR, which lacks TPH2 enzyme activity, dominant-negatively affects full-length TPH2 function, causing reduced 5-HT production. The predicted mRNA for TPH2-TR is present in postmortem brain of rs1386493 carriers. The rs13864923 variant does not appear to be overrepresented in either global or multiplex depression cohorts. However, in combination with other gene variants linked to 5-HT homeostasis, this variant may exhibit important epistatic influences.


Subject(s)
Alternative Splicing , Depression/genetics , Genetic Predisposition to Disease/genetics , Serotonin/biosynthesis , Tryptophan Hydroxylase/genetics , Animals , Brain Stem/metabolism , Cell Line, Transformed , Female , Genetic Predisposition to Disease/psychology , Genotype , Humans , Male , PC12 Cells , Pedigree , Polymorphism, Single Nucleotide/genetics , Rats
4.
Mol Psychiatry ; 15(8): 816-22, 2010 Aug.
Article in English | MEDLINE | ID: mdl-19274051

ABSTRACT

This longitudinal study examined the relationship between 2-year change in white matter hyperintense lesion (WML) volume and polymorphisms in genes coding for the angiotensin-II type 1 and type 2 receptors, AGTR1 A1166C and AGTR2 C3123A, respectively. 137 depressed and 94 non-depressed participants aged >or=60 years were enrolled. Standard clinical evaluations were performed on all participants and blood samples obtained for genotyping. 1.5-T MRI (magnetic resonance imaging) data were obtained at baseline and approximately 2 years later. These scans were processed using a semi-automated segmentation process, which allowed for the calculation of WML volume at each time point. Statistical models were tested for the relationship between change in WML volume and genotype, while also controlling for age, sex, diagnostic strata, baseline WML volume and comorbid cerebrovascular risk factors. In men, AGTR1 1166A allele homozygotes exhibited significantly less change in WML volume than 1166C carriers. We also found that men reporting hypertension (HTN) with the AGTR2 3123C allele exhibit less change in WML volume than hypertensive men with the 3123A allele, or men without HTN. There were no significant relationships between these polymorphisms and change in WML volume in women. No significant gene-gene or gene-depression interactions were observed. Our results parallel earlier observed gender differences of the relationship between other renin-angiotensin system polymorphisms and HTN. Further work is needed to determine whether these observed relationships are secondary to polymorphisms affecting response to antihypertensive medication, and whether antihypertensive medications can slow WML progression and lower the risk of morbidity associated with WMLs.


Subject(s)
Brain/pathology , Depression/genetics , Depression/pathology , Nerve Fibers, Myelinated/pathology , Polymorphism, Genetic/genetics , Receptor, Angiotensin, Type 1/genetics , Receptor, Angiotensin, Type 2/genetics , Aged , Aged, 80 and over , Analysis of Variance , Antidepressive Agents/therapeutic use , Brain/drug effects , Chi-Square Distribution , Depression/drug therapy , Female , Genotype , Humans , Longitudinal Studies , Magnetic Resonance Imaging , Male , Mental Status Schedule , Middle Aged , Sex Factors
6.
Int J Geriatr Psychiatry ; 24(10): 1127-33, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19296553

ABSTRACT

OBJECTIVE: The objective of the current study was to examine the relationship between the COMT Val(158)Met polymorphism and neuropsychological performance in depressed and nondepressed older adults. METHODS: One hundred and twenty-six clinically depressed older adults and 105 nondepressed comparison participants were compared on neuropsychological performance and COMT Val(158)Met (Val/Val, Val/Met, Met/Met). RESULTS: Based on multivariate regression models, the COMT Val(158)Met polymorphism was not associated with cognitive performance among depressed or nondepressed individuals, nor did this polymorphism account for the fact that depressed individuals performed worse than nondepressed individuals on several neuropsychological tests that are typically affected by depression. There was also no difference in frequency of the COMT Val(158)Met alleles between depressed and nondepressed individuals. CONCLUSIONS: Although the current study found no association between COMT Val(158)Met polymorphism on a number of clinical neuropsychological tests that are typically found to be sensitive to depression, differential effects of the COMT Val(158)Met polymorphism on dopamine transmission in psychiatric and non-psychiatric populations may be further clarified by clinical research with neuroscience-based paradigms that segregate cognitive tasks into component processes with precise neural substrates, particularly with respect to the complex functions of the prefrontal cortex. Negative results can be important to narrowing down target processes and understanding the influence of clinical and demographic characteristics in studies of psychiatric genetics.


Subject(s)
Catechol O-Methyltransferase/genetics , Cognition , Depressive Disorder/genetics , Polymorphism, Genetic , Aged , Aging , Female , Genotype , Humans , Male , Middle Aged , Multivariate Analysis , Neuropsychological Tests
7.
Int J Geriatr Psychiatry ; 24(3): 219-25, 2009 Mar.
Article in English | MEDLINE | ID: mdl-18655212

ABSTRACT

OBJECTIVE: The goal of the current study was to examine the neuropsychological profile of magnetic resonance imaging (MRI)-defined subcortical ischemic depression (SID). METHODS: Clinically depressed older adults with MRI-defined SID (n = 70) and depressed elders without SID (n = 75) were compared on neuropsychological performance, depression symptoms, and medical burden. RESULTS: Group comparisons revealed that the SID was associated with worse performance on all neuropsychological measures, but also with greater age, higher cardiac illness burden, and greater deficits in the depression symptoms of self-initiation and concentration. In multivariate regression models, auditory working memory and nonverbal memory remained worse among the SID group after controlling for contributions of age, cardiovascular risk, and depression symptoms. CONCLUSIONS: Although auditory working memory span and nonverbal memory appear to be specifically associated with the ischemic pathology that defines SID, the typical individual with SID is also likely to have a broader profile of neuropsychological deficits than those without SID because they are typically older and have specific depression symptoms that predispose them to compromised neurocognitive performance.


Subject(s)
Brain Ischemia/diagnosis , Dementia, Vascular/diagnosis , Depression/etiology , Aged , Brain Ischemia/physiopathology , Brain Ischemia/psychology , Cross-Sectional Studies , Dementia, Vascular/physiopathology , Dementia, Vascular/psychology , Depression/diagnosis , Female , Geriatric Assessment , Humans , Magnetic Resonance Angiography , Male , Middle Aged , Neuropsychological Tests , Psychometrics , Risk Factors
8.
Mol Psychiatry ; 12(10): 934-45, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17440431

ABSTRACT

Schizophrenia is associated with impairments in neurotransmitter systems and changes in neuronal membrane phospholipids. Several atypical antipsychotic drugs induce weight gain and hypertriglyceridemia. To date, there has not been a comprehensive evaluation and mapping of global lipid changes in schizophrenia, and upon treatment with antipsychotics. Such mapping could provide novel insights about disease mechanisms and metabolic side effects of therapies used for its treatment. We used a specialized metabolomics platform 'lipidomics' that quantifies over 300 polar and nonpolar lipid metabolites (across seven lipid classes) to evaluate global lipid changes in schizophrenia and upon treatment with three commonly used atypical antipsychotics. Lipid profiles were derived for 50 patients with schizophrenia before and after treatment for 2-3 weeks with olanzapine (n=20), risperidone (n=14) or aripiprazole (n=16). Patients were recruited in two cohorts (study I, n=27 and study II, n=23) to permit an internal replication analyses. The change from baseline to post-treatment was then compared among the three drugs. Olanzapine and risperidone affected a much broader range of lipid classes than aripiprazole. Approximately 50 lipids tended to be increased with both risperidone and olanzapine and concentrations of triacylglycerols increased and free fatty acids decreased with both drugs but not with aripiprazole. Phosphatidylethanolamine concentrations that were suppressed in patients with schizophrenia were raised by all three drugs. Drug specific differences were also detected. A principal component analysis (PCA) identified baseline lipid alterations, which correlated with acute treatment response. A more definitive long-term randomized study of these drugs correlating global lipid changes with clinical outcomes could yield biomarkers that define drug-response phenotypes.


Subject(s)
Antipsychotic Agents/pharmacology , Lipid Metabolism/drug effects , Lipids/blood , Schizophrenia/blood , Adult , Analysis of Variance , Antipsychotic Agents/therapeutic use , Cohort Studies , Female , Humans , Male , Principal Component Analysis , Psychiatric Status Rating Scales , Schizophrenia/drug therapy
9.
Int J Geriatr Psychiatry ; 19(1): 9-18, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14716694

ABSTRACT

OBJECTIVE: To examine the safety and efficacy of sertraline augmentation therapy in the treatment of behavioral manifestations of Alzheimer's disease (AD) in outpatients treated with donepezil. METHODS AND MATERIALS: Patients with probable or possible AD, and a Neuropsychiatric Inventory (NPI) total score >5 (with a severity score > or =2 in at least one domain), were treated with donepezil (5-10 mg) for 8 weeks, then randomly assigned to 12 weeks of double-blind augmentation therapy with either sertraline (50-200 mg) or placebo. Primary efficacy measures were the 12-item Neuropsychiatric Inventory (NPI) and the Clinical Global Impression Improvement (CGI-I) and Severity (CGI-S) scales. RESULTS: 24 patients were treated with donepezil+sertraline and 120 patients with donepezil+placebo. There were no statistically significant differences at endpoint on any of the three primary efficacy measures. However, a linear mixed model analysis found modest but statistically significantly greater improvements in the CGI-I score on donepezil+sertraline. Moreover, in a sub-group of patients with moderate-to-severe behavioral and psychological symptoms of dementia, 60% of patients on sertraline vs 40% on placebo (p = 0.006) achieved a response (defined as > or = 50% reduction in a four-item NPI-behavioral subscale). One adverse event (diarrhea) was significantly (p < 0.05) more common in the donepezil+sertraline group compared to the donepezil+placebo group. CONCLUSION: Sertraline augmentation was well-tolerated in this sample of AD outpatients. In addition, post hoc analyses demonstrated a modest but statistically significant advantage of sertraline over placebo augmentation in mixed model analyses and a clinically and statistically significant advantage in a subgroup of patients with moderate-to-severe behavioral and psychological symptoms of dementia.


Subject(s)
Alzheimer Disease/drug therapy , Antidepressive Agents/therapeutic use , Behavioral Symptoms/drug therapy , Selective Serotonin Reuptake Inhibitors/therapeutic use , Sertraline/therapeutic use , Aged , Alzheimer Disease/psychology , Ambulatory Care/methods , Antidepressive Agents/adverse effects , Behavioral Symptoms/etiology , Cholinesterase Inhibitors/therapeutic use , Donepezil , Double-Blind Method , Drug Therapy, Combination , Female , Humans , Indans/therapeutic use , Male , Middle Aged , Neuropsychological Tests , Nootropic Agents/therapeutic use , Piperidines/therapeutic use , Psychiatric Status Rating Scales , Selective Serotonin Reuptake Inhibitors/adverse effects , Sertraline/adverse effects , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...